Larson Financial Group’s Moderna MRNA Stock Holding History

Larson Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-200	Closed	-$2K	–	1143
2021 Q3	$2K	Buy	+200	New	+$73.8K	﹤0.01%	789

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Larson Financial Group's MRNA Position: Q2 2026 in Review

Larson Financial Group reduced its Moderna (MRNA) stake by 10% in Q2 2026, selling an estimated $11.5K and leaving 1,943 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #1023.

Larson Financial Group first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Larson Financial Group held 1,943 shares of Moderna worth $136K as of Q2 2026.
Larson Financial Group sold 223 Moderna shares in Q2 2026, an estimated $11.5K.
Moderna made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1023 holding.
Larson Financial Group first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.